There is paucity of data on the epidemiology of peripapillary choroidal neovascularisartion (PPCNV). Our aim was to determine prevalence of PPCNV in the elderly UK population of Bridlington residents aged ≥65 years.
Eyes with PPCNV in the Bridlington eye assessment project (BEAP) database of 3475 participants were analysed. PPCNV outline was drawn, its area measured, and clock-hour involvement of disc circumference recorded. Location and shortest distance from the lesion edge to fovea were recorded. Masked grading for age-related maculopathy (ARM)/reticular pseudodrusen (RPD) within the ETDRS grid was assigned for each eye using a modified Rotterdam scale. Peripapillary retinal pigment epithelial (RPE) changes/drusen were recorded. Visual acuity (VA) and demographic details analysed separately were merged with grading data.
PPCNV were identified in ten subjects, and were bilateral in two (20%), a population prevalence of 0.29%, and 0.06% bilaterality. Gender-specific prevalence were 0.36% and 0.19% for females and males, respectively. Age ranged from 66 to 85 years [mean 76.3 (SD 6.4)]. PPCNV were located nasal to disc in 41.7%, measuring 0.46–7.93 mm2 [mean 2.81 mm2 (SD 2.82)]. All PPCNV eyes had peripapillary RPE changes. One subject had no ARM, 1 angioid streaks, and 30% RPD. No direct foveal involvement, or reduced VA attributable to PPCNV was observed.
PPCNV were infrequent in this population, more common in females, and often located nasal to the disc, without foveal extension. Peripapillary degenerative changes were universal, and strong association with ARM was observed in eyes with PPCNV. Typically, PPCNV were asymptomatic with VA preservation.
Subscribe to Journal
Get full journal access for 1 year
only $34.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Lopez PF, Green WR. Peripapillary subretinal neovascularization. A review. Retina. 1992;12:147–71.
Wilde C, Patel M, Lakshmanan A, Amankwah R, Dhar-Munshi S, Amoaku W. The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography. Eye. 2015;29:602–9.
Ruben S, Palmer H, Marsh RJ. The visual outcome of peripapillary choroidal neovascular membranes. Acta Ophthalmol. 1994;72:118–21.
Browning DJ, Fraser CM. Ocular conditions associated with peripapillary subretinal neovascularization, their relative frequencies, and associated outcomes. Ophthalmology. 2005;112:1054–61.
Cantrill HL, Burgess D. Peripapillary neovascular membranes in presumed ocular histoplasmosis. Am J Ophthalmol. 1980;89:192–203.
Arkfeld DF, Brockhurst RJ. Peripapillary subretinal neovascularization in peripheral uveitis. Retina. 1985;5:157–60.
Garcia CA, Segundo Pde S, Garcia Filho CA, et al. Intermediate uveitis complicated by choroidal granuloma following subretinal neovascular membrane: case reports. Arq Bras Oftalmol. 2008;71:890–3.
Mehta S, Hariharan L, Ho AC, et al. Peripapillary choroidal neovascularization in pars planitis. J Ophthalmic Inflamm Infect. 2013;3:13.
Shoughy SS, Jaroudi MO, Tabbara KF. Regression of peripapillary choroidal neovascular membrane in a patient with sarcoidosis after oral steroid therapy. Saudi J Ophthalmol. 2014;28:160–2.
Jampol LM, Orth D, Daily MJ, et al. Subretinal neovascularization with geographic (serpiginous) choroiditis. Am J Ophthalmol. 1979;88:683–9.
Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol. 1981;91:177–83.
Wilde C, Poostchi A, Mehta RL, MacNab HK, Hillman JG, Vernon SA, et al. Prevalence of age-related macular degeneration in an elderly UK Caucasian population—The Bridlington Eye Assessment Project: a cross-sectional study. Eye. 2017;31:1042–50. https://doi.org/10.1038/eye.2017.30
Kies JC, Bird AC. Juxtapapillary choroidal neovascularization in older patients. Am J Ophthalmol. 1988;105:11–9.
Silvestri G, Archer DB, Johnston PB. Peripapillary subretinal neovascular membranes: the natural history. Eye. 1993;7:398–402.
Zarubina AV, Neely DC, Clark ME, Huisingh CE, Samuels BC, Zhang Y, et al. Prevalence of subretinal drusenoid deposits in Older Persons with and without age-related macular degeneration by multimodal imaging. Ophthalmology. 2016;123:1090–1100.
Berkow JW. Subretinal neovascularization in senile macular degeneration. Am J Ophthalmol. 1984;97:143–7.
Huisingh C, McGwin G Jr, Neely D, Zarubina A, Clark M, Zhang Y, et al. The association between subretinal drusenoid deposits in older adults in normal macular health and incident age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016;57:739–45.
Cohen SY, m Dubois L, Tadayani R, Delahaye-Mazza C, Debibie C, Quentel G. Prevalence of reticular pseudodrusen in age-related macular degeneration with newly diagnosed choroidal neovascularisation. Br J Ophthalmol. 2007;91:354–9.
Wilde C, Patel M, Lakshmanan A, Morales MA, Dhar-Munshi S, Amoaku WM. Prevalence of reticular pseudodrusen in eyes with newly presenting neovascular age-related macular degeneration. Eur J Ophthalmol. 2015;26:128–34.
Hogg RE, Silva R, Staurenghi G, Murphy G, Santos AR, Rosina C, et al. Clinical characteristics of reticular pseudodrusen in the fellow eye of patients with unilateral neovascular age-related macular degeneration. Ophthalmology. 2014;121:1748–55.
Oh KT, Christmas NJ, Russell SR. Late recurrence and choroidal neovascularization in multiple evanescent white dot syndrome. Retina. 2001;21:182–4.
Wyhinny GJ, Jackson JL, Jampol LM, Caro NC. Subretinal neovascularization following multiple evanescent white-dot syndrome. Arch Ophthalmol. 1990;108:1384–5.
Sarks SH. New vessel formation beneath the retinal pigment epithelium in senile eyes. Br J Ophthalmol. 1973;57:951–65.
Ballatori N, Clarkson TW. Developmental changes in the biliary excretion of methylmercury and glutathione. Science. 1982;216:61–3.
Singerman LJ, Hatem G. Laser treatment of choroidal neovascular membranes in angioid streaks. Retina. 1981;1:75–83.
Mansour AM, Shields JA, Annesley WH Jr., et al. Macular degeneration in angioid streaks. Int J Ophthal. 1988;197:36–41.
Lim JI, Bressler NM, Marsh MJ, Bressler SB. Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthal. 1993;116:414–23.
Binder S. Surgical treatment of peripapillary choroidal neovascularisation. Br J Ophthalmol. 2007;91:990–1.
Kokame GT, Yamaoka S. Subretinal surgery for peripapillary subretinal neovascular membranes. Retina. 2005;25:564–9.
Wolf S, Wald KJ, Remky A, Arend O, Reim M. Evolving peripapillary choroidal neovascular membrane demonstrated by indocyanine green choroidal angiography. Retina. 1994;14:465–7.
Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol. 1973;90:206–17.
This research was funded in part by a Research Grant from the Macular Society UK, Andover, Hants, UK. The Bridlington Eye Assessment Project was funded by an unrestricted grant from Pfizer. We would also like to thank the following organisations for financial support of the Project: Pharmacia, Yorkshire Wolds and Coast Primary Care Trust, The Lords Feoffees of Bridlington, Bridlington Hospital League of Friends, The Hull and East Riding Charitable Trust, The National Eye Research Centre (Yorkshire), The Rotary Club of Bridlington, The Alexander Pigott Wernher Memorial Trust, Bridlington Lions Club, The Inner Wheel Club of Bridlington, Soroptimist International of Bridlington, and The Patricia and Donald Shepherd Charitable Trust. The authors thank Sheila MacNab (Project Manager), and Stephen Brown, Janet Button, Graham Langton, and Mark Kunz (Optometrists) for their work with the Project; John Bapty, Nigel Connell, Peter Jay, and Gillian Poole for their work as the charity trustees of the Bridlington Eye Assessment Project.
WMA: consultant for Abbvie, Alimera, Allergan Inc, Bayer, Novartis, Pfizer, Santen, and Thrombogenics, and has undertaken research sponsored by Allergan, Novartis, and Pfizer. He has received speaker fees and travel grants from Allergan, Bausch and Lomb, Bayer, Novartis and Pfizer. JGH: none. HKM: none. RM: none. MM: none. GM: none. AP: none. SAV: consultant for Allergan and Alcon, and has undertaken research sponsored by Allergan and Pfizer. He has received speaker fees from Allergan, Alcon, Pfizer, Optivue and Topcon. CW: none.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Wilde, C., Poostchi, A., Mehta, R.L. et al. Prevalence of peripapillary choroidal neovascular membranes (PPCNV) in an elderly UK population—the Bridlington eye assessment project (BEAP): a cross-sectional study (2002–2006). Eye 33, 451–458 (2019). https://doi.org/10.1038/s41433-018-0232-y